載入中
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
前收盤價
US$12.545
+US$0.525 · +4.37%
盤中時間採用ET。市場資料可能有所延遲。
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
日內區間
目前US$12.545
52週區間
目前US$12.545
盤中時間採用ET。市場資料可能有所延遲。
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
日內區間
目前US$12.545
52週區間
目前US$12.545
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 7512.8萬 USD | 2883.3萬 USD | 3802.5萬 USD | 4.85億 USD | 3.75億 USD |
| 銷貨成本 | 2882.1萬 USD | — | — | 6643.6萬 USD | 4551.6萬 USD |
| 毛利 | 4630.7萬 USD | 2883.3萬 USD | 3802.5萬 USD | 4.19億 USD | 3.3億 USD |
| 研究與開發 | 1.87億 USD | 1.67億 USD | 1.76億 USD | 1.08億 USD | 6206.2萬 USD |
| 銷售、一般及管理費用 | 7658.1萬 USD | 8549萬 USD | 7517.9萬 USD | 6675.5萬 USD | 4876.1萬 USD |
| 營業費用 | 2.63億 USD | 3.44億 USD | 2.75億 USD | 2.02億 USD | 1.25億 USD |
| 利息收入 | 2832.9萬 USD | 3847.3萬 USD | 4224.7萬 USD | 1607.9萬 USD | 333萬 USD |
| 利息支出 | — | — | — | 404.5萬 USD | 522.5萬 USD |
| 折舊和攤銷 | 2882.1萬 USD | 9699.8萬 USD | 3089.4萬 USD | 3310.2萬 USD | 1725萬 USD |
| 營業利益 | −2.17億 USD | −3.15億 USD | −2.37億 USD | 2.17億 USD | 2.04億 USD |
| 淨利 | −1.46億 USD | −1.63億 USD | −1.46億 USD | 1.59億 USD | 1.53億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$14.75
上漲空間 17.58%報告持有此股票曝險的交易所交易基金。
iShares Biotechnology ETFIBB2322.89萬0.22%108.2億 USD0.44%US$206.49+3.00%
iShares Genomics Immunology and Healthcare ETFIDNA822.42萬2.58%3.2億 USD0.47%US$42.17+4.33%
State Street SPDR Portfolio Developed World ex-US ETFSPDW691.13萬0.02%404.62億 USD0.03%US$49.98+0.64%
Fidelity Nasdaq Composite Index ETFONEQ104.5萬0.01%109.4億 USD0.21%US$107.81+0.63%
Avantis U.S. Equity ETFAVUS77.9萬0.01%148.63億 USD0.15%US$130.52+0.35%
Virtus Biotech Clinical Trials ETFBBC72.79萬1.78%4099.65萬 USD0.65%US$44.1456+2.08%
Avantis U.S. Small Cap Equity ETFAVSC47.67萬0.02%30.82億 USD0.25%US$69.98+0.03%
Invesco RAFI Developed Markets ex-U.S. Small-Mid ETFPDN37.5萬0.11%3.47億 USD0.47%US$45.715+0.83%iShares Biotechnology ETFIBBiShares Genomics Immunology and Healthcare ETFIDNAState Street SPDR Portfolio Developed World ex-US ETFSPDWFidelity Nasdaq Composite Index ETFONEQAvantis U.S. Equity ETFAVUSVirtus Biotech Clinical Trials ETFBBCAvantis U.S. Small Cap Equity ETFAVSCInvesco RAFI Developed Markets ex-U.S. Small-Mid ETFPDNAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
